NCT00879060
Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
See it on ClinicalTrials.gov ↗53 people
28.3%
71.7%
15 womenmiddle line = equal numbers38 men
- Phase
- PHASE4
- Paid for by
- Tufts Medical Center
- Finished
- 2012-11
- Health conditions
- Myocardial Fibrosis, Hypertrophic Cardiomyopathy
- Who could join
- Anyone
- Ages
- 18 Years – 70 Years
- Average age
- mean 41 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“Pregnant or breast feeding”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnant or breast feeding”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Calculated creatinine clearance \<30 ml/min using Cockcroft-Gault formula.”
- No diabetes
Women with diabetes were turned away.
“…ated with elevated serum concentrations of PIIINP (e.g., chronic liver disease, diabetes mellitus, tumors, pulmonary fibrosis, bone and rheumatoid diseases, extensive wounds) or PINP (e.g., alcoholic liver disease, metabolic bone disease, t…”
Study titles and rules are shown in their original English.